2024年11月5日 · Regardless of time periods for MRD assessment, NPM1 qPCR provided excellent prognostic risk stratification: p=0.05 on day 0-120, p<0.0001 on day 121-240, and P<0.0001 on day 241-365. Conclusion: NPM1 qPCR MRD monitoring has become standard of care in AML management.

2023年1月6日 · To identify which parts of the modular NPM1 structure are responsible for delaying Aβ 42 aggregation, we designed truncated variants: NPM1 120, which contains only the NTD with the A1 tract, NPM1 188, which includes the NTD and the acidic tracts A1-3, NPM1 240, which encompasses the NTD and the entire IDR, and NPM1 240-294, which represents ...

2024年12月17日 · NPM1 is the most abundant protein of the nucleolus and its restraint in such subnuclear membrane-less structure relies on both mere affinity for nucleolar components [4] and the nucleolar...

Nucleophosmin 1 (NPM1) is also known as nucleophosmin (NPM), nucleolar phosphoprotein B23, and numatrin in mammals, and NO38 in amphibians. NPM1 was first discovered as a nucleolar protein in rat liver cells and Novikoff hepatoma ascites cells by two-dimensional polyacrylamide gel electrophoresis (Table 10.1) (Orrick et al. 1973).

2023年11月11日 · NPM1突变AML是成人 AML 中最大的分子学亚组（30-35%），可通过分子技术和免疫组化进行识别，两者联合使用时可解决困难的诊断问题（包括识别髓系肉瘤和外显子12以外的 NPM1 突变）。 根据2022年欧洲白血病网 (ELN)，确定NPM1（和FLT3）的突变状态是基于基因的 AML 风险分层的必须步骤，通过 RT-qPCR 监测MRD，结合 ELN 风险分层，可指导缓解后阶段的治疗决策。 Blood Cancer Discovery近日发表一篇文章，对 NPM1 突变 AML 的诊断、风 …

2024年11月5日 · To evaluate its clinical relevance, we divided MRD testing into 3 different time periods after initial diagnosis (i.e., 0-120 days, 121-240 days, 240-365 days), and evaluate the implication of NPM1 copy numbers by the 4 groups, on RFS.

2024年8月22日 · Recent studies have revealed various clinical applications of NPM1 mutations in AML treatment, particularly in measurable residual disease analyses that target mutant NPM1 transcripts and in potential therapeutic applications of menin inhibitors and XPO-1 inhibitors for AML with mutated NPM1.

2013年2月25日 · In this review, we focus on the leukemia-associated NPM1 C-terminal domain and describe its structure, function, and the effect exerted by leukemic mutations. Finally, we discuss the possibility to target NPM1 for the treatment of cancer and, in particular, of AML patients with mutated NPM1 gene.

(a) NPM1 has a modular architecture, composed of a folded N-terminal pentamerization domain (NTD, residues 1-120), an intrinsically disordered region (IDR, residues 120-240) containing three...

Nucleophosmin 1 (NPM1) is an abundant nucleolar protein that forms large oligomers and undergoes liquid–liquid phase separation by binding RNA or ribosomal proteins. It provides the scaffold for ribosome assembly but also prevents protein …